MX2018011480A - Metodos de intervencion temprana para prevenir o aminorar toxicidad. - Google Patents
Metodos de intervencion temprana para prevenir o aminorar toxicidad.Info
- Publication number
- MX2018011480A MX2018011480A MX2018011480A MX2018011480A MX2018011480A MX 2018011480 A MX2018011480 A MX 2018011480A MX 2018011480 A MX2018011480 A MX 2018011480A MX 2018011480 A MX2018011480 A MX 2018011480A MX 2018011480 A MX2018011480 A MX 2018011480A
- Authority
- MX
- Mexico
- Prior art keywords
- receptors
- toxicity
- therapy
- treatment
- cell
- Prior art date
Links
- 230000001988 toxicity Effects 0.000 title abstract 7
- 231100000419 toxicity Toxicity 0.000 title abstract 7
- 238000000034 method Methods 0.000 title abstract 6
- 238000011282 treatment Methods 0.000 abstract 10
- 210000004027 cell Anatomy 0.000 abstract 6
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 abstract 4
- 108091008874 T cell receptors Proteins 0.000 abstract 4
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 abstract 4
- 238000002659 cell therapy Methods 0.000 abstract 4
- 239000003795 chemical substances by application Substances 0.000 abstract 4
- 108020003175 receptors Proteins 0.000 abstract 4
- 102000005962 receptors Human genes 0.000 abstract 4
- 238000002560 therapeutic procedure Methods 0.000 abstract 4
- 230000002924 anti-infective effect Effects 0.000 abstract 2
- 230000003115 biocidal effect Effects 0.000 abstract 2
- 108700010039 chimeric receptor Proteins 0.000 abstract 2
- -1 e.g. Proteins 0.000 abstract 2
- 229960001438 immunostimulant agent Drugs 0.000 abstract 2
- 239000003022 immunostimulating agent Substances 0.000 abstract 2
- 230000003308 immunostimulating effect Effects 0.000 abstract 2
- 238000009169 immunotherapy Methods 0.000 abstract 2
- 210000000265 leukocyte Anatomy 0.000 abstract 2
- 238000012544 monitoring process Methods 0.000 abstract 2
- 230000002688 persistence Effects 0.000 abstract 2
- 239000006041 probiotic Substances 0.000 abstract 2
- 230000000529 probiotic effect Effects 0.000 abstract 2
- 235000018291 probiotics Nutrition 0.000 abstract 2
- 230000009261 transgenic effect Effects 0.000 abstract 2
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000000977 initiatory effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Dermatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662311906P | 2016-03-22 | 2016-03-22 | |
| US201662417287P | 2016-11-03 | 2016-11-03 | |
| US201662429722P | 2016-12-02 | 2016-12-02 | |
| PCT/US2017/023676 WO2017165571A1 (en) | 2016-03-22 | 2017-03-22 | Early intervention methods to prevent or ameliorate toxicity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018011480A true MX2018011480A (es) | 2019-03-28 |
Family
ID=58609964
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018011480A MX2018011480A (es) | 2016-03-22 | 2017-03-22 | Metodos de intervencion temprana para prevenir o aminorar toxicidad. |
Country Status (13)
| Country | Link |
|---|---|
| US (5) | US11518814B2 (enExample) |
| EP (3) | EP4015536A1 (enExample) |
| JP (3) | JP7048571B2 (enExample) |
| KR (1) | KR20190021200A (enExample) |
| CN (1) | CN109476743A (enExample) |
| AU (2) | AU2017238218B2 (enExample) |
| BR (1) | BR112018069251A2 (enExample) |
| CA (1) | CA3018588A1 (enExample) |
| ES (1) | ES2907557T3 (enExample) |
| MA (2) | MA44486A (enExample) |
| MX (1) | MX2018011480A (enExample) |
| RU (1) | RU2018136877A (enExample) |
| WO (1) | WO2017165571A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150320799A1 (en) | 2012-12-20 | 2015-11-12 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| SG10202104804PA (en) | 2014-10-20 | 2021-06-29 | Juno Therapeutics Inc | Methods and compositions for dosing in adoptive cell therapy |
| ES2901795T3 (es) | 2015-12-04 | 2022-03-23 | Juno Therapeutics Inc | Métodos y composiciones relacionadas con la toxicidad asociada con la terapia celular |
| JP7048571B2 (ja) | 2016-03-22 | 2022-04-05 | シアトル チルドレンズ ホスピタル （ディービーエイ シアトル チルドレンズ リサーチ インスティテュート） | 毒性を予防または改善するための早期介入法 |
| JP7282521B2 (ja) | 2016-04-08 | 2023-05-29 | パーデュー・リサーチ・ファウンデイション | Ｃａｒ ｔ細胞療法のための方法および組成物 |
| RU2019120398A (ru) * | 2016-12-03 | 2021-01-12 | Джуно Терапьютикс, Инк. | Способы определения дозировки cart-клеток |
| EP3579870A4 (en) | 2017-02-07 | 2020-12-30 | Seattle Children's Hospital (DBA Seattle Children's Research Institute) | PHOSPHOLIPID ETHER (PLE) T CAR-LYMPHOCYTE TUMOR (CTCT) TARGETING AGENTS |
| CA3053539A1 (en) | 2017-02-27 | 2018-08-30 | Juno Therapeutics, Inc. | Compositions, articles of manufacture and methods related to dosing in cell therapy |
| WO2018160622A1 (en) | 2017-02-28 | 2018-09-07 | Endocyte, Inc. | Compositions and methods for car t cell therapy |
| US11564946B2 (en) | 2017-11-01 | 2023-01-31 | Juno Therapeutics, Inc. | Methods associated with tumor burden for assessing response to a cell therapy |
| WO2019109053A1 (en) * | 2017-12-01 | 2019-06-06 | Juno Therapeutics, Inc. | Methods for dosing and for modulation of genetically engineered cells |
| AU2019209432A1 (en) * | 2018-01-22 | 2020-08-06 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Methods of use for CAR T cells |
| CN111936518A (zh) | 2018-02-06 | 2020-11-13 | 西雅图儿童医院（Dba西雅图儿童研究所） | 对fl-ple标记的肿瘤表现出最佳的t细胞功能的荧光素特异性car |
| BR122023022189A2 (pt) | 2018-02-16 | 2024-02-20 | Incyte Corporation | Usos de inibidores da via de jak1 para o tratamento de distúrbios relacionados a citocinas |
| WO2019165237A1 (en) | 2018-02-23 | 2019-08-29 | Endocyte, Inc. | Sequencing method for car t cell therapy |
| WO2019170845A1 (en) * | 2018-03-09 | 2019-09-12 | Ospedale San Raffaele S.R.L. | Il-1 antagonist and toxicity induced by cell therapy |
| CN111989344A (zh) * | 2018-03-09 | 2020-11-24 | 科济生物医药（上海）有限公司 | 用于治疗肿瘤的方法和组合物 |
| US20210263045A1 (en) * | 2018-04-06 | 2021-08-26 | The Board Of Regents Of The University Of Texas System | Prediction and treatment of immunotherapeutic toxicity |
| WO2021028469A1 (en) * | 2019-08-12 | 2021-02-18 | Sitokine Limited | Compositions and methods for treating cytokine release syndrome and neurotoxicity |
| ES2970382T3 (es) * | 2019-08-14 | 2024-05-28 | Rigel Pharmaceuticals Inc | Método para bloquear o mejorar el síndrome de liberación de citocinas |
| US11045546B1 (en) | 2020-03-30 | 2021-06-29 | Cytodyn Inc. | Methods of treating coronavirus infection |
| US20230366893A1 (en) * | 2020-09-29 | 2023-11-16 | Washington University | Methods to determine risk of neurotoxicity |
| WO2022125670A1 (en) | 2020-12-08 | 2022-06-16 | Incyte Corporation | Jak1 pathway inhibitors for the treatment of vitiligo |
| DK4333840T3 (da) | 2021-05-03 | 2025-11-24 | Incyte Corp | Jak1-vejinhibitorer til behandling af prurigo nodularis |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US265209A (en) | 1882-09-26 | Automatic feeder for perforators | ||
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4452773A (en) | 1982-04-05 | 1984-06-05 | Canadian Patents And Development Limited | Magnetic iron-dextran microspheres |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
| US4795698A (en) | 1985-10-04 | 1989-01-03 | Immunicon Corporation | Magnetic-polymer particles |
| IN165717B (enExample) | 1986-08-07 | 1989-12-23 | Battelle Memorial Institute | |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
| ATE114507T1 (de) | 1988-12-28 | 1994-12-15 | Stefan Miltenyi | Verfahren sowie materialien zur hochgraduierten magnetischen abspaltung biologischer materialien. |
| US5200084A (en) | 1990-09-26 | 1993-04-06 | Immunicon Corporation | Apparatus and methods for magnetic separation |
| EP0557459B1 (en) | 1990-11-13 | 1997-10-22 | Immunex Corporation | Bifunctional selectable fusion genes |
| CA2147466A1 (en) | 1992-10-20 | 1994-04-28 | Just P. J. Brakenhoff | Interleukin-6 receptor antagonists |
| US6080407A (en) * | 1993-05-17 | 2000-06-27 | The Picower Institute For Medical Research | Diagnostic assays for MIF |
| WO1994028143A1 (en) | 1993-05-21 | 1994-12-08 | Targeted Genetics Corporation | Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene |
| US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| DE19608753C1 (de) | 1996-03-06 | 1997-06-26 | Medigene Gmbh | Transduktionssystem und seine Verwendung |
| WO1997034634A1 (en) | 1996-03-20 | 1997-09-25 | Sloan-Kettering Institute For Cancer Research | Single chain fv constructs of anti-ganglioside gd2 antibodies |
| WO2000014257A1 (en) | 1998-09-04 | 2000-03-16 | Sloan-Kettering Institute For Cancer Research | Fusion receptors specific for prostate-specific membrane antigen and uses thereof |
| AU2472400A (en) | 1998-10-20 | 2000-05-08 | City Of Hope | CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies |
| WO2001094944A2 (en) | 2000-06-02 | 2001-12-13 | Memorial Sloan-Kettering Cancer Center | Artificial antigen presenting cells and methods of use thereof |
| EP1334188B1 (en) | 2000-11-07 | 2006-08-30 | City of Hope | Cd19-specific redirected immune cells |
| US7070995B2 (en) | 2001-04-11 | 2006-07-04 | City Of Hope | CE7-specific redirected immune cells |
| US20090257994A1 (en) | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| US20030170238A1 (en) | 2002-03-07 | 2003-09-11 | Gruenberg Micheal L. | Re-activated T-cells for adoptive immunotherapy |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| US20050129671A1 (en) | 2003-03-11 | 2005-06-16 | City Of Hope | Mammalian antigen-presenting T cells and bi-specific T cells |
| WO2007147623A2 (en) * | 2006-06-22 | 2007-12-27 | Cellact Pharma Gmbh | A novel target in the treatment of cytokine release syndrome |
| PT2856876T (pt) | 2007-03-30 | 2018-03-28 | Memorial Sloan Kettering Cancer Center | Expressão constitutiva de ligantes co-estimulatórios em linfócitos t adotivamente transferidos |
| EP3338895B1 (en) | 2007-12-07 | 2022-08-10 | Miltenyi Biotec B.V. & Co. KG | Sample processing systems and methods |
| US8479118B2 (en) | 2007-12-10 | 2013-07-02 | Microsoft Corporation | Switching search providers within a browser search box |
| US20120164718A1 (en) | 2008-05-06 | 2012-06-28 | Innovative Micro Technology | Removable/disposable apparatus for MEMS particle sorting device |
| JP5173594B2 (ja) | 2008-05-27 | 2013-04-03 | キヤノン株式会社 | 管理装置、画像形成装置及びそれらの処理方法 |
| PL3006459T3 (pl) | 2008-08-26 | 2022-01-17 | City Of Hope | Sposób i kompozycje dla wzmocnionego działania efektorowego komórek t przeciw guzowi nowotworowemu |
| TWI440469B (zh) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
| ES2911246T3 (es) | 2009-11-03 | 2022-05-18 | Hope City | Receptor del factor de crecimiento epidérmico truncado (EGFRT) para selección de células T transducidas |
| CA2810465C (en) * | 2010-09-16 | 2018-10-02 | Baliopharm Ag | Anti-hutnfr1 antibody |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| KR101976882B1 (ko) | 2011-03-23 | 2019-05-09 | 프레드 헛친슨 켄서 리서치 센터 | 세포 면역요법용 방법 및 조성물 |
| US8398282B2 (en) | 2011-05-12 | 2013-03-19 | Delphi Technologies, Inc. | Vehicle front lighting assembly and systems having a variable tint electrowetting element |
| JP6368243B2 (ja) | 2011-11-11 | 2018-08-08 | フレッド ハッチンソン キャンサー リサーチ センター | がんのためのサイクリンａ１に標的化されたｔ細胞免疫療法 |
| JP6850528B2 (ja) | 2012-02-13 | 2021-03-31 | シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート | 二重特異性キメラ抗原受容体およびその治療的使用 |
| WO2013126726A1 (en) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Double transgenic t cells comprising a car and a tcr and their methods of use |
| RU2665548C2 (ru) | 2012-05-03 | 2018-08-30 | Фред Хатчинсон Кансэр Рисёч Сентер | Способ получения клеток, экспрессирующих т-клеточный рецептор |
| ES2778701T3 (es) * | 2012-07-13 | 2020-08-11 | The Trustees Of The Univ Of Pennsylvania Center For Technology Transfer | Gestión de toxicidad para la actividad antitumoral de CAR |
| PL2884999T3 (pl) | 2012-08-20 | 2021-07-05 | Fred Hutchinson Cancer Research Center | Sposób i kompozycje do immunoterapii komórkowej |
| RU2729401C2 (ru) | 2012-10-02 | 2020-08-06 | Мемориал Слоан-Кеттеринг Кэнсер Сентер | Композиции и способы для иммунотерапии |
| US9405601B2 (en) | 2012-12-20 | 2016-08-02 | Mitsubishi Electric Corporation | In-vehicle apparatus and program |
| UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| US9108442B2 (en) | 2013-08-20 | 2015-08-18 | Ricoh Company, Ltd. | Image forming apparatus |
| IL303543A (en) * | 2015-02-18 | 2023-08-01 | Enlivex Therapeutics Rdo Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| WO2017035362A1 (en) * | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Use of complement pathway inhibitor compounds to mitigate adoptive t-cell therapy associated adverse immune responses |
| US11747346B2 (en) | 2015-09-03 | 2023-09-05 | Novartis Ag | Biomarkers predictive of cytokine release syndrome |
| JP7048571B2 (ja) | 2016-03-22 | 2022-04-05 | シアトル チルドレンズ ホスピタル （ディービーエイ シアトル チルドレンズ リサーチ インスティテュート） | 毒性を予防または改善するための早期介入法 |
| CN120285179A (zh) | 2016-07-15 | 2025-07-11 | 诺华股份有限公司 | 使用与激酶抑制剂组合的嵌合抗原受体治疗和预防细胞因子释放综合征 |
-
2017
- 2017-03-22 JP JP2019500746A patent/JP7048571B2/ja active Active
- 2017-03-22 KR KR1020187030514A patent/KR20190021200A/ko not_active Withdrawn
- 2017-03-22 BR BR112018069251A patent/BR112018069251A2/pt not_active IP Right Cessation
- 2017-03-22 RU RU2018136877A patent/RU2018136877A/ru not_active Application Discontinuation
- 2017-03-22 MA MA044486A patent/MA44486A/fr unknown
- 2017-03-22 EP EP21207779.6A patent/EP4015536A1/en active Pending
- 2017-03-22 EP EP24221056.5A patent/EP4545143A3/en active Pending
- 2017-03-22 MA MA71266A patent/MA71266A/fr unknown
- 2017-03-22 MX MX2018011480A patent/MX2018011480A/es unknown
- 2017-03-22 AU AU2017238218A patent/AU2017238218B2/en active Active
- 2017-03-22 US US16/087,488 patent/US11518814B2/en active Active
- 2017-03-22 CA CA3018588A patent/CA3018588A1/en active Pending
- 2017-03-22 WO PCT/US2017/023676 patent/WO2017165571A1/en not_active Ceased
- 2017-03-22 ES ES17719044T patent/ES2907557T3/es active Active
- 2017-03-22 CN CN201780031706.6A patent/CN109476743A/zh active Pending
- 2017-03-22 EP EP17719044.4A patent/EP3433276B1/en not_active Revoked
-
2022
- 2022-03-24 JP JP2022047991A patent/JP7528143B2/ja active Active
- 2022-12-02 US US18/061,196 patent/US11760804B2/en active Active
- 2022-12-05 US US18/061,939 patent/US20230212298A1/en active Pending
-
2023
- 2023-06-06 US US18/329,987 patent/US12098208B2/en active Active
-
2024
- 2024-07-24 AU AU2024205049A patent/AU2024205049A1/en active Pending
- 2024-07-24 JP JP2024118592A patent/JP2024156736A/ja active Pending
- 2024-09-09 US US18/828,243 patent/US20240425608A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019509351A (ja) | 2019-04-04 |
| EP4015536A1 (en) | 2022-06-22 |
| CA3018588A1 (en) | 2017-09-28 |
| MA71266A (fr) | 2025-04-30 |
| MA44486A (fr) | 2019-01-30 |
| ES2907557T3 (es) | 2022-04-25 |
| AU2024205049A1 (en) | 2024-08-15 |
| EP4545143A2 (en) | 2025-04-30 |
| US20230212298A1 (en) | 2023-07-06 |
| US12098208B2 (en) | 2024-09-24 |
| WO2017165571A1 (en) | 2017-09-28 |
| EP4545143A3 (en) | 2025-07-23 |
| JP7528143B2 (ja) | 2024-08-05 |
| BR112018069251A2 (pt) | 2019-01-22 |
| AU2017238218B2 (en) | 2024-05-02 |
| JP2022088489A (ja) | 2022-06-14 |
| JP7048571B2 (ja) | 2022-04-05 |
| KR20190021200A (ko) | 2019-03-05 |
| US20190112379A1 (en) | 2019-04-18 |
| US11518814B2 (en) | 2022-12-06 |
| US20230322937A1 (en) | 2023-10-12 |
| AU2017238218A1 (en) | 2018-10-11 |
| RU2018136877A (ru) | 2020-04-22 |
| CN109476743A (zh) | 2019-03-15 |
| US20230091447A1 (en) | 2023-03-23 |
| JP2024156736A (ja) | 2024-11-06 |
| US11760804B2 (en) | 2023-09-19 |
| US20240425608A1 (en) | 2024-12-26 |
| EP3433276B1 (en) | 2021-12-22 |
| EP3433276A1 (en) | 2019-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018011480A (es) | Metodos de intervencion temprana para prevenir o aminorar toxicidad. | |
| Schmulson et al. | Microbiota, gastrointestinal infections, low-grade inflammation, and antibiotic therapy in irritable bowel syndrome (IBS): an evidence-based review | |
| MX351975B (es) | Composiciones y metodos para el tratamiento de infecciones y tumores. | |
| MX2016005159A (es) | Metodos de diagnostico y tratamiento de trastornos eosinofilicos. | |
| BR112017010268A2 (pt) | agente de ligação; composição de diagnóstico; kit de diagnóstico; métodos de diagnóstico de uma infecção bacteriana ou de diferenciação entre uma infecção bacteriana e uma infecção de viral; para descartar uma infecção bacteriana em um indivíduo; para descartar uma infecção viral em um indivíduo; para considerar uma infecção bacteriana em um indivíduo; para considerar uma infecção viral em um indivíduo; para distinguir entre uma infecção bacteriana ou mista e uma infecção viral em um indivíduo; para fornecer uma recomendação de tratamento para um indivíduo; para fornecer uma recomendação de teste de diagnóstico para um indivíduo; para descartar uma doença infecciosa; para identificação do tipo de infecção; e dispositivo para o diagnóstico de infecções bacterianas | |
| WO2013006474A3 (en) | Requlatora t cells and methods of identifying and isolating them using cd6 -expression or the combination of cd4, cd25 and cd127 | |
| MX2017011486A (es) | Métodos de detección y cuantificación de il-13 y sus usos en el diagnóstico y tratamiento de enfermedades asociadas a th2. | |
| MX2015000438A (es) | Manejo de toxicidad para actividad antitumoral de cars. | |
| CO2018009561A2 (es) | Métodos para tratar la depresión con antagonistas del receptor de orexina-2 | |
| WO2012174338A3 (en) | Method of selecting therapeutic indications | |
| MY192843A (en) | Antibodies specific for tgf-beta | |
| EP3825419A3 (en) | Diagnostic, prognostic and therapeutic uses of long noncoding rnas for heart disease and regenerative medicine | |
| MX2018003893A (es) | Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos. | |
| EA201691020A1 (ru) | Способы лечения и предотвращения вызываемой аллогенными антителами хронической болезни "трансплантат против хозяина" | |
| HK1214752A1 (zh) | 由产甲烷菌引起或与之相关的疾病及病状的诊断、选择及治疗方法 | |
| BR112015010039A2 (pt) | tratamento de câncer com pomalidomida em um individuo com disfunção renal | |
| NZ754427A (en) | Regulation of glucose metabolism using anti-cgrp antibodies | |
| MY191800A (en) | Use of carrimycin in mycobacterium tuberculosis infection resistance | |
| BR112015030757A2 (pt) | desfibrilador para uma operação de modo misto de cardioversão; e sistema de desfibrilação | |
| MX370570B (es) | Marcador para trastornos de la esfingomielinasa acida y sus usos. | |
| MX377275B (es) | Ensayo para detectar poblaciones celulares linfocitos t colaboradores 1 (th1) y linfocitos t colaboradores (th2). | |
| WO2014100746A3 (en) | Tspan 33 is a candidate for antibody targeted therapy for the treatment of b cell hodgkin lymphomas | |
| Doobaree et al. | The United Kingdom immune thrombocytopenia (UK-ITP) registry: preliminary findings on bleeding events experienced by its participants | |
| WO2014126796A3 (en) | Methods of diagnosing, treating and monitoring diabetic retinopathy | |
| WO2013049362A3 (en) | Method of treating multiple sclerosis by intrathecal depletion of b cells and biomarkers to select patients with progressive multiple sclerosis |